Syndax Pharmaceuticals (SNDX) to Release Quarterly Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $86.32 million for the quarter.

Syndax Pharmaceuticals Trading Up 2.4 %

Shares of Syndax Pharmaceuticals stock opened at $16.38 on Monday. The company has a 50 day moving average of $13.97 and a 200-day moving average of $16.93. Syndax Pharmaceuticals has a 1-year low of $12.06 and a 1-year high of $25.34. The company has a market cap of $1.40 billion, a PE ratio of -4.51 and a beta of 0.90.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on SNDX shares. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. HC Wainwright restated a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. The Goldman Sachs Group raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Citigroup raised their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. Finally, Scotiabank cut their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Neil Gallagher sold 4,618 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).